|
|
NewsLarial Proteomics Executive White Paper
Larial Proteomics is a 4 year old, Toronto-based CRO whose mission is to empower biomedical researchers and life scientists with the capabilities of unlocking the mysteries of protein structure and function. Larial provides cost-effective, analytical services for companies seeking to acquire or expand their intellectual property portfolios. Larial works with companies in the fermentation, biotechnology and pharmaceutical sectors and it is involved in a variety of academic projects. Larial helps its clients build innovative new technology platforms to enable them to capture and implement new sources of information.
Typical projects include therapeutics development and testing, fermentation strain analysis, biological probe development and protein structure/function studies. Larial enters the strategic planning process with clients at an early stage by developing scientific algorithms that ensure production of high quality analytical samples that yield compelling results.
The company has successfully developed a number of platform technologies including RepliCassTM and RepliPlateTM for high throughput mass spectrometry imaging and high density peptide arraying. Larial helps companies evaluate new technologies and investors judge the value of new technologies in the marketplace. The company also helps its clients broaden their product application base to improve sales and better position their technologies in the marketplace.
Research on the mass spectometry (MS) service market, especially in North America, shows that it has become over-serviced by subsidized, public sector institutions and various CROs that often suffer from insufficient revenues. The narrow scope provided by most MS services is typically focused on protein, drug metabolism and small molecule chemistry targeted mostly at developing pharmaceutical based IP. Surprisingly, there is a highly underserviced market for MS analyses performed within a GLP/GMP laboratory setting. Revenue generation opportunities have also been identified by Larial that are outside of the pharmaceutical/biotech sphere but are equally significant: forensic analysis, food science research (OMAFRA), fermentation analysis, winery/LCBO QA testing, environmental analysis. These industries have not been systematically exploited by most MS service providers and an opportunity exists to establish a series of unique, high margin MS services tailored to the specific needs of these sectors.
The principal strategies that are driving business development at Larial are: - product development that is focused on relieving market pain - deriving revenues from high value, high margin analytical services - capitalizing on high cost public and private sector scientific discoveries to identify commercially important, unprotected IP - developing linking and quantal technologies that provide long term profitability through sustained market dominance - finding novel commercialization trade routes that reduce acceptance barriers for new technologies - limiting infrastructure building to immediate business opportunities and using cost-effective purchasing and selling mechanisms to maintain or create infrastructure value
For More Information Contact:
|
|
Send mail to holiver@whatifwhatnext.com with
questions or comments about this web site.
|
